Published in final edited form as:

Prenat Diagn. 2017 May ; 37(5): 435–439. doi:10.1002/pd.5028.

Elevation of glycosaminoglycans in the amniotic fluid of a fetus with mucopolysaccharidosis VII:

Prenatal diagnosis of an MPS VII fetus

Francyne Kubaski^{1,2,3,†}, Ana Carolina Brusius-Facchin^{4,†}, Robert W. Mason^{1,2}, Pravin Patel⁵, Maira G. Burin⁴, Kristiane Michelin-Tirelli⁴, Rejane Gus Kessler⁴, Fernanda Bender⁴, Sandra Leistner-Segal^{4,6}, Carolina A. Moreno⁷, Denise P. Cavalcanti⁷, Roberto Giugliani^{3,4,6,8}, and Shunji Tomatsu^{1,2}

¹Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA

²Department of Biological Sciences, University of Delaware, Newark, DE, USA

³INAGEMP, Porto Alegre, Brazil

⁴Medical Genetics Service, HCPA, Porto Alegre, Brazil

⁵Graduate School of Biomedical Sciences, Thomas Jefferson University, Philadelphia, PA, USA

⁶Post Graduation Program on Medical Sciences, UFRGS, Porto Alegre, Brazil

⁷Perinatal Genetic Program, Department of Medical Genetics, UNICAMP, Campinas, Brazil

⁸Department of Genetics, UFRGS, Porto Alegre, Brazil

Abstract

Objective—The aim of this study was to quantify GAGs in amniotic fluid (AF) from an MPS VII fetus compared with age-matched fetuses obtained from normal pregnancies.

Method—Disaccharides were measured by liquid chromatography tandem mass spectrometry (LC/MS/MS), compared to age-matched controls. Enzyme assay was performed in AF supernatant or cultured amniocytes. *GUSB* was analyzed by next generation sequencing using Ion Torrent Personal Genome Machine with a customized panel.

Results—No activity of β -glucuronidase was detected in fetal cells. The pregnancy was spontaneously terminated in the third trimester. Genetic studies identified a homozygous mutation of p.N379D (c.1135A>G) in the *GUSB* gene. LC/MS/MS showed that chondroitin sulfate, dermatan sulfate, heparan sulfate, and keratan sulfate levels were markedly increased in the MPS VII AF, compared to those in age-matched control AF (DS, HS, and C6S more than 10 $\times$ than age-matched controls; C4S and KS more than 3 times higher).

* Address for correspondence and reprints: Shunji Tomatsu MD, Ph.D, Professor, Department of Biomedical Research Nemours/Alfred I. duPont Hospital for Children. 1600 Rockland Rd., Wilmington, DE. 19899-0269, Office Tel: 302-298-7336, Fax: 302-651-6888; stomatsu@nemours.org.

[†]The first two authors should be regarded as joint first authors.

Conflict of Interest: Francyne Kubaski, Ana Carolina Brusius-Facchin, Robert W. Mason, Pravin Patel, Maira G. Burin, Kristiane Michelin-Tirelli, Rejane G. Kessler, Fernanda Bender, Sandra Leistner-Segal, Carolina Moreno, Denise P. Cavalcanti, Roberto Giugliani, and Shunji Tomatsu declare that they have no conflict of interests.

Conclusion—This is the first report of specific GAG analysis in AF from an MPS VII fetus, indicating that GAG elevation in AF occurs by 21 weeks of gestation and could be an additional tool for prenatal diagnosis of MPS VII and potentially other MPS types.

Keywords

Mucopolysaccharidosis VII; Sly syndrome; prenatal diagnosis; glycosaminoglycans; β -glucuronidase; tandem mass spectrometry

INTRODUCTION

Mucopolysaccharidosis VII (MPS VII; Sly syndrome) (OMIM#253220) is an autosomal recessive lysosomal storage disorder (LSD) caused by a deficiency of β -glucuronidase (GUSB). This enzyme deficiency leads to accumulation of chondroitin sulfate (CS), dermatan sulfate (DS), and heparan sulfate (HS).¹ The first MPS VII case was described in 1973 by Dr. William S. Sly.²

Patients with MPS VII have a broad range of clinical signs and symptoms including; coarse facies, skeletal dysplasia, short stature, hernias, hepatosplenomegaly, neurological impairment, and corneal clouding. The clinical spectrum ranges from a severe form with lethal hydrops fetalis to attenuated forms with survival into adulthood despite physical and cognitive impairment.^{3–12}

GUSB is localized to chromosome 7q21.11, and the 21kb gene contains 12 exons.^{13–16} Several groups have independently reported many mutations within *GUSB* that result in different MPS VII phenotypes.^{10, 17–32} Sixty-three mutations have been described according to the Human Gene Mutation database (HGMD) as of November, 2016.

The incidence of MPS VII is not well documented, and many cases are not diagnosed due to spontaneous abortion.^{33–42} Clinical manifestations of MPS usually do not appear at birth; however, accumulation of GAGs has been reported histopathologically in the human fetus (MPS I, II, III, IVA) and placenta (MPS II, VI),^{43–45} indicating that the disease process starts and can be detected prior to appearance of clinical signs and symptoms.

Prenatal studies for MPS VII have been performed primarily to measure GUSB deficiency and for histopathologic analysis.^{46–54} Until now, no study has reported on the quantification of GAGs in fetal specimens with MPS VII. The aim of this study was to quantify GAGs in amniotic fluid (AF) from an MPS VII fetus and to compare with age-matched AF obtained from normal pregnancies.

METHODS

Tandem mass spectrometry

Chondroitin-4-sulfate (C4S), chondroitin-6-sulfate (C6S), dermatan sulfate (DS), heparan sulfate (HS-OS, NS and diS₁) and keratan sulfate (mono-KS and di-KS) were measured in AF by liquid chromatography tandem mass spectrometry (LC/MS/MS) and compared with AF of five age-matched controls corrected by protein.

10 µl of AF was added to a 96 well Omega 10K filter plate (Pall Co, MI) with 90 µl of 50 mM Tris HCL (pH 7.0) with a 96-well receiver plate at the bottom. Samples were incubated with a mixture of internal standard (chondrosine), chondroitinase (B, ABC and ACII), heparitinase and keratanase II (Seikagaku Co, Japan) according to the same method described by Kubaski et al.⁵⁵

DS and C4S were measured as 2-acetamido-2-deoxy 3-O- (β-D-glucopyranosyluronic acid)- 4- O- D- sulfo-galactose digested by chondroitinase B or ACII to generate DS or C4S, respectively. C6S was measured as 2-acetamido-2-deoxy-3-O- (β-D-glucopyranosyluronic acid)- 6-O-D-sulfo-galactose digested by chondroitinase ABC. HS was measured by 2-acetamido-2-deoxy-4-O-(4-deoxy-α-L-threo-hexopyranosyluronic acid)-D-glucose (HS-0S), 2-deoxy-2-sulfamino 4-O-(4-deoxy-α-L-threo-hex-4-enopyranosyluronic acid)-D-glucose (HS-NS) and 2-deoxy-2-sulfamino-4-(4-deoxy-α-L-threo-hex-4-enopyranosyluronic acid)-6-O-sulfo-D-glucose (HS-diS₁) digested by heparitinase. KS was measured by Gal(6S)β1 → 4GlcNAc(6S) (di-KS) and Galβ1 → 4GlcNAc(6S) (mono-KS) digested by keratanase II.

Specific precursor ion and its product, *m/z* and liquid chromatography were used to quantify each disaccharide, respectively (354.3, 193.1 for IS; 378.3, 175.1 for HS-0S and DS; 458.4, 300.2 for C4S; 458.4, 282.1 for C6S; 416, 138.1 for HS-NS; 496.3, 416.3 for HS-diS₁; 542, 461.9 for di-KS; 462, 97 for mono-KS).

Molecular analysis

Molecular analyses were conducted by next generation sequencing using Ion Torrent Personal Genome Machine (Thermo Scientific™) with a customized panel (Ion AmpliSeq™ Thermo Scientific™) including the *GUSB* gene. Data was analyzed on Ion Torrent suite and Ion reporter (Thermo Scientific™) version 5.0.

This study was approved by the ethics committee of Hospital de Clínicas de Porto Alegre (project # 03066) and informed consent was obtained from the parents for prenatal diagnosis and molecular analysis.

RESULTS

The proband was a female fetus from non-consanguineous parents that presented with hydrops fetalis at 19 weeks of pregnancy and spontaneously died at 25 weeks of pregnancy. The mother, 31 year-old, had three previous pregnancies (one stillbirth and two children that died in the first year of life). No investigation was performed on these previous siblings.

Since the most common causes of non-immune hydrops fetalis, as congenital infection, malformations and chromosomal abnormalities, were ruled out, a lysosomal storage disorder was suspected. Thus, the levels of GAGs in AF at 21 weeks of pregnancy were measured using tandem mass spectrometry.

We observed that the concentration of GAGs found within the patient's AF was greatly elevated (10 SD) when compared to age-matched controls (Table 1).

Levels of DS, HS, and C6S were at least 10 fold higher in MPS VII than those in the age-matched controls, and C4S and KS were over 3 fold higher. C4S, C6S, HS-0S, and HS-NS were elevated as primary storage materials. Levels of mono-sulfated and di-sulfated KS were also elevated, secondarily. HS-diS1 level was not elevated (Table 1).

Due to the elevated levels of DS, HS, and C6S, a diagnosis of MPS VII was suspected. Biochemical analysis showed the very low enzymatic activity of GUSB in cultured amniocytes and AF, confirming the initial suspicion. The moderately low activity of β -galactosidase and a slight reduction in the activity of neuraminidase were also observed, but these alterations were not considered clinically relevant (Table 2). α -Mannosidase and total hexosaminidase were evaluated in AF supernatant to exclude mucopolidosis II/III.⁵⁶

Molecular analysis

Molecular analyses were conducted by next generation sequencing with a customized panel including the *GUSB* gene. 36,000 reads were obtained with 1,500 reads per amplicon. The Asn379Asp (p.N379D) (c.1135A>G) alteration was found in a homozygous state for the affected fetus and in a heterozygous state in both parents. This is the first report of p.N379D substitution in GUSB.

Asn379 is conserved in GUSB in 50 species including humans, mice, and *E. coli*, and is a buried residue⁵⁷. Consequently, alteration of the neutral Asn to acidic Asp is likely to disrupt the structure of the protein. The PredicSNP² program indicates that this change is likely deleterious to the protein structure⁵⁸. More molecular studies are needed to confirm the function of Asn379 in the structure or function of GUSB.

DISCUSSION

We have demonstrated that AF surrounding a fetus with MPS VII at 21 weeks of gestational age has a marked elevation of GAGs, including secondary storage of KS, indicating that AF is valuable for measuring GAG level to detect MPS before birth. In 1993, Chabás et al. described the use of chorionic villus (CVS) and amniotic fluid (AF) to measure GUSB activity for prenatal diagnosis.⁴⁹ Reduced levels of GUSB activity have subsequently been detected in these tissues for several MPS VII fetuses.^{50, 51, 53, 59} Groener et al. used two-dimensional electrophoresis to demonstrate elevated DS and CS in fetal blood in a confirmed MPS VII fetus.⁵⁴ However, no prior study has been reported on quantification of the levels of GAGs in CVS or AF. Our study shows that all GAGs and their subclasses, except for HS-diS1, are noticeably elevated in AF of the affected fetus compared with those in the age-matched controls and that the biochemical finding of GAGs is matched with the previous pathological findings of GAG accumulation in the affected fetuses as described above.^{60–62} We and others have shown that KS is secondarily elevated in plasma (serum) and urine in several types of MPS and LSDs (in addition to MPS IV in which the deficient enzyme is directly involved in the catabolism of KS).^{63–65} We previously proposed that secondary elevation of KS can be caused by several factors including the release of KS from damaged bone and cartilage.^{66–68} However, newborn DBS from MPS I, II, or III subjects showed no elevation of KS at birth.⁶⁹ The elevated KS in AF surrounding the MPS VII fetus

in this study could suggest a more severe phenotype, including skeletal damage and/or developmental impairment *in utero*.

CONCLUSION

In this first report of quantification of GAGs in AF surrounding an MPS VII fetus using LC/MS/MS, we show that GAG elevation is present at 21 weeks of gestation. Thus, we suggest that GAG measurements in AF may become a valuable additional tool for the diagnosis of MPS VII and potentially other MPS types.

Acknowledgments

We thank Dr. Ivan Adzhubey for technical assistance with Polyphen and bioinformatics support provided. R.W.M. and S.T. were supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of NIH under grant number P30GM114736. S.T. was supported by National Institutes of Health grant R01HD065767. F.K. was supported by INAGEMP and Conselho Nacional de Desenvolvimento Científico e Tecnológico from Brazil (CNPq) and INAGEMP.

References

1. Elizabeht, Neufeld, Joseph, Muenzer. The Mucopolysaccharidoses. New York: McGraw-Hill; 2001.
2. Sly WS, Quinton BA, McAlister WH, Rimoin DL. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. *J Pediatr*. 1973; 82(2):249–257. [PubMed: 4265197]
3. Beaudet AL, DiFerrante NM, Ferry GD, et al. Variation in the phenotypic expression of beta-glucuronidase deficiency. *J Pediatr*. 1975; 86(3):388–394. [PubMed: 803560]
4. Pfeiffer RA, Kresse H, Bäumer N, Sattinger E. Beta-glucuronidase deficiency in a girl with unusual clinical features. *Eur J Pediatr*. 1977; 126(3):155–161. [PubMed: 144057]
5. Gitzelmann R, Wiesmann UN, Spycher MA, et al. Unusually mild course of beta-glucuronidase deficiency in two brothers (mucopolysaccharidosis VII). *Helv Paediatr Acta*. 1978; 33(4–5):413–428. [PubMed: 101485]
6. Sewell AC, Gehler J, Mittermaier G, Meyer E. Mucopolysaccharidosis type VII (beta-glucuronidase deficiency): a report of a new case and a survey of those in the literature. *Clin Genet*. 1982; 21(6): 366–373. [PubMed: 6813001]
7. Lee JE, Falk RE, Ng WG, Donnell GN. Beta-glucuronidase deficiency. A heterogeneous mucopolysaccharidosis. *Am J Dis Child*. 1985; 139(1):57–59. [PubMed: 3155909]
8. Stangenberg M, Lingman G, Roberts G, Ozand P. Mucopolysaccharidosis VII as cause of fetal hydrops in early pregnancy. *Am J Med Genet*. 1992; 44(2):142–144. [PubMed: 1456282]
9. de Kremer RD, Givogri I, Argaraña CE, et al. Mucopolysaccharidosis type VII (beta-glucuronidase deficiency): a chronic variant with an oligosymptomatic severe skeletal dysplasia. *Am J Med Genet*. 1992; 44(2):145–152. [PubMed: 1456283]
10. Vervoort R, Islam MR, Sly WS, et al. Molecular analysis of patients with beta-glucuronidase deficiency presenting as hydrops fetalis or as early mucopolysaccharidosis VII. *Am J Hum Genet*. 1996; 58(3):457–471. [PubMed: 8644704]
11. Yamada Y, Kato K, Sukegawa K, et al. Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. *Bone Marrow Transplant*. 1998; 21(6):629–634. [PubMed: 9543069]
12. Walter-Nicolet E, Rakza T, Storme L, et al. A new case of mucopolysaccharidosis VII presenting as non immune hydrops fetalis. *Eur J Pediatr*. 2003; 162(7–8):520–521. [PubMed: 12748853]
13. Francke U. The human gene for beta glucuronidase is on chromosome 7. *Am J Hum Genet*. 1976; 28(4):357–362. [PubMed: 941903]
14. Oshima A, Kyle JW, Miller RD, et al. Cloning, sequencing, and expression of cDNA for human beta-glucuronidase. *Proc Natl Acad Sci U S A*. 1987; 84(3):685–689. [PubMed: 3468507]

15. Miller RD, Hoffmann JW, Powell PP, et al. Cloning and characterization of the human beta-glucuronidase gene. *Genomics*. 1990; 7(2):280–283. [PubMed: 2347593]
16. Schwartz CE, Stanislovitis P, Phelan MC, et al. Deletion mapping of plasminogen activator inhibitor, type I (PLANHI) and beta-glucuronidase (GUSB) in 7q21----q22. *Cytogenet Cell Genet*. 1991; 56(3–4):152–153. [PubMed: 2055109]
17. Tomatsu S, Sukegawa K, Ikedo Y, et al. Molecular basis of mucopolysaccharidosis type VII: replacement of Ala619 in beta-glucuronidase with Val. *Gene*. 1990; 89(2):283–287. [PubMed: 2115490]
18. Fukuda S, Tomatsu S, Sukegawa K, et al. Molecular analysis of mucopolysaccharidosis type VII. *J Inherit Metab Dis*. 1991; 14(5):800–804. [PubMed: 1779626]
19. Shipley JM, Klinkenberg M, Wu BM, et al. Mutational analysis of a patient with mucopolysaccharidosis type VII, and identification of pseudogenes. *Am J Hum Genet*. 1993; 52(3):517–526. [PubMed: 7680524]
20. Wu BM, Sly WS. Mutational studies in a patient with the hydrops fetalis form of mucopolysaccharidosis type VII. *Hum Mutat*. 1993; 2(6):446–457. [PubMed: 8111413]
21. Vervoort R, Lissens W, Liebaers I. Molecular analysis of a patient with hydrops fetalis caused by beta-glucuronidase deficiency, and evidence for additional pseudogenes. *Hum Mutat*. 1993; 2(6):443–445. [PubMed: 8111412]
22. Wu BM, Tomatsu S, Fukuda S, et al. Overexpression rescues the mutant phenotype of L176F mutation causing beta-glucuronidase deficiency mucopolysaccharidosis in two Mennonite siblings. *J Biol Chem*. 1994; 269(38):23681–23688. [PubMed: 8089138]
23. Yamada S, Tomatsu S, Sly WS, et al. Four novel mutations in mucopolysaccharidosis type VII including a unique base substitution in exon 10 of the beta-glucuronidase gene that creates a novel 5'-splice site. *Hum Mol Genet*. 1995; 4(4):651–655. [PubMed: 7633414]
24. Islam MR, Vervoort R, Lissens W, et al. beta-Glucuronidase P408S, P415L mutations: evidence that both mutations combine to produce an MPS VII allele in certain Mexican patients. *Hum Genet*. 1996; 98(3):281–284. [PubMed: 8707294]
25. Vervoort R, Buist NR, Kleijer WJ, et al. Molecular analysis of the beta-glucuronidase gene: novel mutations in mucopolysaccharidosis type VII and heterogeneity of the polyadenylation region. *Hum Genet*. 1997; 99(4):462–468. [PubMed: 9099834]
26. Vervoort R, Gitzelmann R, Bosshard N, et al. Low beta-glucuronidase enzyme activity and mutations in the human beta-glucuronidase gene in mild mucopolysaccharidosis type VII, pseudodeficiency and a heterozygote. *Hum Genet*. 1998; 102(1):69–78. [PubMed: 9490302]
27. Storch S, Wittenstein B, Islam R, et al. Mutational analysis in longest known survivor of mucopolysaccharidosis type VII. *Hum Genet*. 2003; 112(2):190–194. [PubMed: 12522561]
28. Schwartz I, Silva LR, Leistner S, et al. Mucopolysaccharidosis VII: clinical, biochemical and molecular investigation of a Brazilian family. *Clin Genet*. 2003; 64(2):172–175. [PubMed: 12859417]
29. Gratz M, Kunert-Keil C, John U, et al. Identification and functional analysis of genetic variants of the human beta-glucuronidase in a German population sample. *Pharmacogenet Genomics*. 2005; 15(12):875–881. [PubMed: 16272959]
30. Tomatsu S, Montañó AM, Dung VC, et al. Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome). *Hum Mutat*. 2009; 30(4):511–519. [PubMed: 19224584]
31. Gómez AM, García-Robles R, Suárez-Obando F. Estimation of the mucopolysaccharidoses frequencies and cluster analysis in the Colombian provinces of Cundinamarca and Boyacá. *Biomédica: revista del Instituto Nacional de Salud*. 2012; 32(4):602. [PubMed: 23715235]
32. Khan FI, Shahbaaz M, Bisetty K, et al. Large scale analysis of the mutational landscape in β -glucuronidase: A major player of mucopolysaccharidosis type VII. *Gene*. 2016; 576(1 Pt 1):36–44. [PubMed: 26415878]
33. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. *Hum Genet*. 1997; 101(3):355–358. [PubMed: 9439667]
34. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. *Hum Genet*. 1999; 105(1–2):151–156. [PubMed: 10480370]

35. Stone DL, Sidransky E. Hydrops fetalis: lysosomal storage disorders in extremis. *Adv Pediatr.* 1999; 46:409–440. [PubMed: 10645471]
36. Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. *Am J Med Genet A.* 2003; 123A(3):310–313. [PubMed: 14608657]
37. Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. *J Inherit Metab Dis.* 2005; 28(6):1011–1017. [PubMed: 16435194]
38. Malm G, Lund AM, Månsson J, Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. *Acta Paediatr.* 2008; 97(11):1577–1581. [PubMed: 18681890]
39. Lin H, Lin S, Chuang C, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984–2004. *Am J Med Genet A.* 2009; 149A(5):960–964. [PubMed: 19396827]
40. Muenzer J. Overview of the mucopolysaccharidoses. *Rheumatology (Oxford).* 2011; 50(Suppl 5): 4. [PubMed: 21078626]
41. Whybra C, Mengel E, Russo A, et al. Lysosomal storage disorder in non-immunological hydrops fetalis (NIHF): more common than assumed? Report of four cases with transient NIHF and a review of the literature. *Orphanet J Rare Dis.* 2012; 7:86. [PubMed: 23137060]
42. Montañó AM, Lock-Hock N, Steiner RD, et al. Clinical course of sly syndrome (mucopolysaccharidosis type VII). *J Med Genet.* 2016; 53(6):403–418. [PubMed: 26908836]
43. Beck M, Braun S, Coerdts W, et al. Fetal presentation of Morquio disease type A. *Prenat Diagn.* 1992; 12(12):1019–1029. [PubMed: 1287637]
44. Martin JJ, Ceuterick C. Prenatal pathology in mucopolysaccharidoses: a comparison with postnatal cases. *Clin Neuropathol.* 1983; 2(3):122–127. [PubMed: 6226467]
45. Baldo G, Matte U, Artigalas O, et al. Placenta analysis of prenatally diagnosed patients reveals early GAG storage in mucopolysaccharidoses II and VI. *Mol Genet Metab.* 2011; 103(2):197–198. [PubMed: 21427013]
46. Lissens W, Dedobbeleer G, Foulon W, et al. Beta-glucuronidase deficiency as a cause of prenatally diagnosed non-immune hydrops fetalis. *Prenat Diagn.* 1991; 11(6):405–410. [PubMed: 1833732]
47. Stangenberg M, Lingman G, Roberts G, Ozand P. Mucopolysaccharidosis VII as cause of fetal hydrops in early pregnancy. *Am J Med Genet.* 1992; 44(2):142–144. [PubMed: 1456282]
48. Kagie MJ, Kleijer WJ, Huijman JG, et al. beta-Glucuronidase deficiency as a cause of fetal hydrops. *Am J Med Genet.* 1992; 42(5):693–695. [PubMed: 1632440]
49. Chabás A, Guardiola A. beta-Glucuronidase deficiency: identification of an affected fetus with simultaneous sampling of chorionic villus and amniotic fluid. *Prenat Diagn.* 1993; 13(6):429–433. [PubMed: 8372067]
50. Nelson J, Kenny B, O'Hara D, et al. Foamy changes of placental cells in probable beta glucuronidase deficiency associated with hydrops fetalis. *J Clin Pathol.* 1993; 46(4):370–371. [PubMed: 8496396]
51. Van Dorpe J, Moerman P, Pecceu A, et al. Non-immune hydrops fetalis caused by beta-glucuronidase deficiency (mucopolysaccharidosis VII). Study of a family with 3 affected siblings. *Genet Couns.* 1996; 7(2):105–112. [PubMed: 8831129]
52. Molyneux AJ, Blair E, Coleman N, Daish P. Mucopolysaccharidosis type VII associated with hydrops fetalis: histopathological and ultrastructural features with genetic implications. *J Clin Pathol.* 1997; 50(3):252–254. [PubMed: 9155679]
53. Van Eyndhoven HW, Ter Brugge HG, Van Essen AJ, Kleijer WJ. Beta-glucuronidase deficiency as cause of recurrent hydrops fetalis: the first early prenatal diagnosis by chorionic villus sampling. *Prenat Diagn.* 1998; 18(9):959–962. [PubMed: 9793981]
54. Groener JE, de Graaf FL, Poorthuis BJ, Kanhai HH. Prenatal diagnosis of lysosomal storage diseases using fetal blood. *Prenat Diagn.* 1999; 19(10):930–933. [PubMed: 10521818]
55. Kubaski F, Mason RW, Nakatomi A, et al. Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry. *J Inherit Metab Dis.* 2016
56. Burin MG, Scholz AP, Gus R, et al. Investigation of lysosomal storage diseases in nonimmune hydrops fetalis. *Prenat Diagn.* 2004; 24(8):653–657. [PubMed: 15305357]

57. Hassan MI, Waheed A, Grubb JH, et al. High resolution crystal structure of human β -glucuronidase reveals structural basis of lysosome targeting. *PLoS ONE*. 2013; 8(11):e79687. [PubMed: 24260279]
58. Bendl J, Stourac J, Salanda O, et al. PredictSNP: robust and accurate consensus classifier for prediction of disease-related mutations. *PLoS Comput Biol*. 2014; 10(1):e1003440. [PubMed: 24453961]
59. Molyneux AJ, Blair E, Coleman N, Daish P. Mucopolysaccharidosis type VII associated with hydrops fetalis: histopathological and ultrastructural features with genetic implications. *J Clin Pathol*. 1997; 50(3):252–254. [PubMed: 9155679]
60. Beck M, Braun S, Coerdts W, et al. Fetal presentation of Morquio disease type A. *Prenat Diagn*. 1992; 12(12):1019–1029. [PubMed: 1287637]
61. Martin JJ, Ceuterick C. Prenatal pathology in mucopolysaccharidoses: a comparison with postnatal cases. *Clin Neuropathol*. 1983; 2(3):122–127. [PubMed: 6226467]
62. Baldo G, Matte U, Artigalas O, et al. Placenta analysis of prenatally diagnosed patients reveals early GAG storage in mucopolysaccharidoses II and VI. *Mol Genet Metab*. 2011; 103(2):197–198. [PubMed: 21427013]
63. Tomatsu S, Okamura K, Maeda H, et al. Keratan sulphate levels in mucopolysaccharidoses and mucopolipidoses. *J Inher Metab Dis*. 2005; 28(2):187–202. [PubMed: 15877208]
64. Shimada T, Tomatsu S, Mason RW, et al. Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB. *JIMD Rep*. 2015; 21:1–13. [PubMed: 25712379]
65. Auray-Blais C, Lavoie P, Maranda B, Boutin M. Evaluation of urinary keratan sulfate disaccharides in MPS IVA patients using UPLC-MS/MS. *Bioanalysis*. 2016; 8(3):179–191. [PubMed: 26805456]
66. Tomatsu S, Okamura K, Maeda H, et al. Keratan sulphate levels in mucopolysaccharidoses and mucopolipidoses. *J Inher Metab Dis*. 2005; 28(2):187–202. [PubMed: 15877208]
67. Tomatsu S, Shimada T, Mason RW, et al. Establishment of glycosaminoglycan assays for mucopolysaccharidoses. *Metabolites*. 2014; 4(3):655–679. [PubMed: 25116756]
68. Shimada T, Tomatsu S, Mason RW, et al. Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB. *JIMD Rep*. 2015; 21:1–13. [PubMed: 25712379]
69. Kubaski F, Mason RW, Nakatomi A, et al. Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry. *J Inher Metab Dis*. 2016

What is already known about the topic?

- Mucopolysaccharidosis VII (MPS VII; Sly Syndrome) is an autosomal recessive disorder caused by deficiency of β -glucuronidase, leading to accumulation of primary glycosaminoglycans (GAGs);
- MPS VII has a broad clinical spectrum from the most severe lethal hydrops fetalis to attenuated forms with survival into adulthood despite somatic and cognitive impairment;
- GAGs are elevated in a fetus with MPS VII.

What does this study add?

- Not only primary GAGs (HS, DS) but KS are accumulated as early as 21 weeks of gestation;
- This is the first report of p.N379D substitution in GUSB.
- Quantification of GAGs by mass spectrometry applies to prenatal diagnosis, prognosis, and screening for MPS;

Table 1AF GAG levels from patient and age-matched controls (mean $\pm$ SD)

GAG	GAG levels (ng/mg protein)		
	Age-matched controls (mean $\pm$ SD)	Patient	z-score
DS	61 $\pm$ 44	712	15
C4S	142 $\pm$ 56	543	7
C6S	57 $\pm$ 19	621	29
HS-0S	59 $\pm$ 25	891	33
HS-NS	12 $\pm$ 5	142	25
HS-diS ₁	4 $\pm$ 3	2	-1
mono-KS	131 $\pm$ 91	361	2
di-KS	6 $\pm$ 2	25	8

DS: dermatan sulfate; HS: heparan sulfate; CS: chondroitin sulfate; KS: keratan sulfate.

Table 2

Biochemical diagnosis of MPS VII by enzyme activity assay in cultured amniocytes or AF supernatant

Enzyme	Enzyme Activity	
	Normal Range	Patient
β -glucuronidase ¹	40–254	0.34
α -iduronidase ¹	92–264	156
α -mannosidase ²	1.25–21	20
Neuraminidase ¹	30–68	25
β -galactosidase ¹	521–1783	281
β -glucosidase ¹	207–596	218
N-acetylgalactosamine 6 sulfate sulfatase ¹	55–212	71
Hexosaminidase ²	378–2901	979

¹Enzyme activity in cultured amniocytes (nmol/h/mg protein)

²Enzyme activity in amniotic fluid supernatant (nmol/h/mL)